Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jae-Gook Shin

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
International Journal of Antimicrobial Agents|May 9, 2023
Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohortTran Minh Hung, Rannissa Puspita Jayanti, Ho Young Lee, et al.
International Journal of Antimicrobial Agents|November 17, 2023
Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposurePham Quang Hoa, Hyun Kuk Kim, Tae Won Jang, et al.
Frontiers in Pharmacology|June 12, 2023
Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearanceRyunha Kim, Rannissa Puspita Jayanti, Hongyeul Lee, et al.
Plos One|December 23, 2024
Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation studyNguyen Tran Nam Tien, Vu Ngan Binh, Pham Thi Thanh Ha, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 25, 2015
Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East AsiansMahn-Won Park, Sung Ho Her, Chan Joon Kim, et al.
Tuberculosis (Edinburgh, Scotland)|February 25, 2023
Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosisSoedarsono Soedarsono, Rannissa Puspita Jayanti, Ni Made Mertaniasih, et al.
BMC Pulmonary Medicine|November 24, 2023
Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort databaseWoo Jung Seo, Hyeon-Kyoung Koo, Ji Yeon Kang, et al.
Plos One|April 15, 2026
Correction: Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposureRannissa Puspita Jayanti, Yong-Soon Cho, Soedarsono Soedarsono, et al.
Plos One|January 29, 2026
Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposureRannissa Puspita Jayanti, Yong-Soon Cho, Soedarsono Soedarsono, et al.
Blood|March 6, 2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsNita A Limdi, Mia Wadelius, Larisa Cavallari, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
International Journal of Antimicrobial Agents|May 9, 2023
Recommendation of pharmacokinetics/pharmacodynamics target of ethambutol to suppress tuberculosis resistance: A population pharmacokinetics study on a large prospective cohortTran Minh Hung, Rannissa Puspita Jayanti, Ho Young Lee, et al.
International Journal of Antimicrobial Agents|November 17, 2023
Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposurePham Quang Hoa, Hyun Kuk Kim, Tae Won Jang, et al.
Frontiers in Pharmacology|June 12, 2023
Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearanceRyunha Kim, Rannissa Puspita Jayanti, Hongyeul Lee, et al.
Plos One|December 23, 2024
Optimization of meropenem continuous infusion based on Monte Carlo simulation integrating with degradation studyNguyen Tran Nam Tien, Vu Ngan Binh, Pham Thi Thanh Ha, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 25, 2015
Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East AsiansMahn-Won Park, Sung Ho Her, Chan Joon Kim, et al.
Tuberculosis (Edinburgh, Scotland)|February 25, 2023
Development of population pharmacokinetics model and Bayesian estimation of rifampicin exposure in Indonesian patients with tuberculosisSoedarsono Soedarsono, Rannissa Puspita Jayanti, Ni Made Mertaniasih, et al.
BMC Pulmonary Medicine|November 24, 2023
Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: Center for Personalized Precision Medicine of Tuberculosis (cPMTb) cohort databaseWoo Jung Seo, Hyeon-Kyoung Koo, Ji Yeon Kang, et al.
Plos One|April 15, 2026
Correction: Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposureRannissa Puspita Jayanti, Yong-Soon Cho, Soedarsono Soedarsono, et al.
Plos One|January 29, 2026
Population pharmacokinetics model of pyrazinamide to optimize tuberculosis treatment: An interethnic cohort study of diabetes mellitus effect on drug exposureRannissa Puspita Jayanti, Yong-Soon Cho, Soedarsono Soedarsono, et al.
Blood|March 6, 2010
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsNita A Limdi, Mia Wadelius, Larisa Cavallari, et al.
Pageof 26